Dr. Reddy's Reports Q4 & FY26 Results, Highlights Semaglutide Approvals & Strong Growth in Key Markets
Summary
Dr. Reddy's Laboratories reported mixed Q4 and full-year FY26 financial results, with underlying growth excluding specific items, alongside significant product development wins including generic semaglutide approvals in Canada and India.
Key Events
-
Q4 & FY26 Financial Results
Q4 FY26 revenues were 7,516 cr (down 12% YoY), while full-year FY26 revenues reached 33,593 cr (up 5% YoY). Excluding specific items, Q4 EBITDA grew 13% and PAT grew 29%, indicating underlying profitability.
-
Semaglutide Approvals & Launches
The company secured Health Canada approval for its generic Semaglutide Injection, becoming the first company to do so. It also launched Obeda®, India's first DCGI-approved generic semaglutide injection, and received DCGI approval for generic semaglutide tablets in India.
-
Positive Regulatory Outcome
The USFDA concluded its inspection at the Srikakulam formulations facility with a 'Voluntary Action Indicated' (VAI) classification, a positive regulatory development.
-
Pipeline & Portfolio Updates
The Biologics Licence Application (BLA) for the abatacept biosimilar (IV) was accepted for review by the USFDA. However, the trial for Eftilagimod alfa was discontinued by its partner, and certain CAR-T R&D programs were rationalized.
Analysis
This filing details Dr. Reddy's Laboratories' Q4 and full-year FY26 financial results, which show mixed performance but strong underlying growth when adjusted for specific items like a shelf stock adjustment for lenalidomide and impairment charges. Crucially, the company announced significant progress in its product pipeline, including being the first to secure approval for generic semaglutide injection in Canada and launching it in India. These regulatory and product development wins are key future growth drivers, especially for a major drug like semaglutide. While North America revenues faced headwinds, other key markets like India and Emerging Markets delivered double-digit growth, demonstrating geographic diversification. The positive USFDA inspection outcome for a key facility also reduces regulatory risk.
At the time of this filing, RDY was trading at $12.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.2B. The 52-week trading range was $12.19 to $16.17. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.